2026 ASCO® Annual Meeting

Discover how our comprehensive diagnostic intelligence platform transforms vast datasets into insights to ensure that no patient is left behind in the pursuit of better outcomes. Beyond the clinic, our foundation models redefine the R&D landscape—de-risking discovery and accelerating drug development.

Add to calendar

*Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Stop by our booth to experience live demos of our latest technologies and discover how we are leveraging Al to advance precision medicine.

Poster Presentations

◆ = Powered by AI
● = Powered by Tempus+

Saturday, May 30th

9:00 am – 12:00 pm CT
​

◆ Impact of the Taylor Cancer Research Center (TCRC) and Tempus AI TIME Partnership on Clinical Trial Start-up and Accrual
Presenter: John Nemunaitis, Taylor Family Research Foundation
Poster Board: 483; Abstract number for publication: 1565


◆ Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success
Presenter: Boleslaw Leszek Osinski, Tempus AI, Inc.
Collaborating Institutions: Cedars-Sinai Medical Center
Poster Board: 536; Abstract number for publication: 1618


◆● AI-driven RNA-based Homologous Recombination Deficiency algorithm predicts first-line platinum response in metastatic pancreatic cancer.
Presenter: Hannah J Glover, Tempus AI, Inc.
Collaborating Institutions: University of Pennsylvania; University of California San Diego
Poster Board: 193; Abstract number for publication: 4210


Screening for intrinsic and acquired resistance mutations to anti-EGFR in real-world MSS colorectal cancer data
Presenter: Matthew B Maxwell, Tempus AI, Inc.
Collaborating Institutions: The University of Texas MD Anderson Cancer Center
Poster Board: 324; Abstract number for publication: 3557


KMT2C mutation identifies an immunotherapy-sensitive subset of gastrointestinal cancers: a large real-world analysis
Presenter: Bruno Bockorny, Beth Israel Deaconess Medical Center
Poster Board: 332; Abstract number for publication: 3565


● Evaluation of homologous recombination deficiency (HRD) in gastric cancer: Real-world prevalence and outcomes with first-line (1L) platinum-based therapy
Presenter: Dani Ran Castillo, City of Hope Comprehensive Cancer Center
Collaborating Institutions: Harbor-UCLA Medical Center, Loma Linda University, University of California San Francisco (UCSF), Bridgeport Hospital
Poster Board: 22; Abstract number for publication: 4039
​
​
1:30 pm – 4:30 pm CT
​
● A new HLA genotyping algorithm shows extremely high accuracy and concordance between tumor and normal samples.
Presenter: Ariane Lozac'hmeur, Tempus AI, Inc.
Collaborating Institutions: Stanford University
Poster Board: 374; Abstract number for publication: 2584


◆ Development and clinical utility of an H&E-based tumor origin prediction model
Presenter: Qiyuan Hu, Tempus AI, Inc.
Poster Board: 158; Abstract number for publication: 3021


● ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy
Presenter: Malvika Pillai, Tempus AI, Inc.
Collaborating Institutions: Harvard Medical School, Northwestern University, University of Pittsburgh Medical Center
Poster Board: 199; Abstract number for publication: 3062


● Target-specific therapy for actionable and approved tumor-agnostic biomarkers: Influence on survival in rare cancers
Presenter: Razelle Kurzrock, Medical College of Wisconsin
Poster Board: 260; Abstract number for publication: 3123


First-Line Lenvatinib Versus Dabrafenib plus Trametinib (D+T) in BRAF-Mutated Differentiated Thyroid Cancer (DTC): Insights from Real-World Data
Presenter: Wilson Ngai, Eisai Inc.
Poster Board: 509; Abstract number for publication: 6052


● Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors
Presenter: Afshin Dowlati, University Hospitals Seidman Cancer Center and Case Western Reserve University
Collaborating Institutions: Roswell Park Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Whitehawk Therapeutics, Hoag Memorial Hospital Presbyterian, Translational Genomics Research Institute
Poster Board: 219; Abstract number for publication: 3082


◆ Multiomic machine learning integration of DNA and RNA to predict immunotherapy benefit in advanced MSS-CRC and rare cancers
Presenter: Michelle Ting-Lin, Tempus AI, Inc.
Collaborating Institutions: University of Minnesota-Twin Cities, Baylor University Medical Center
Poster Board: 321; Abstract number for publication: 2531


Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): a translational analysis of the AtezoTRIBE study
Presenter: Veronica Conca, Azienda Ospedaliera Universitaria Pisana and University of Pisa, Italy
Collaborating Institutions: Veneto Institute of Oncology (IOV - IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, Tricase City Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, AUSL Romagna, University of Bologna
Poster Board: 365; Abstract number for publication: 2575
​
​

Sunday, May 31st

9:00 am – 12:00 pm CT
​
◆● Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early- stage NSCLC biomarker testing
Presenter: Melina Elpi Marmarelis, University of Pennsylvania
Collaborating Institutions: TriHealth Cancer Institute, YUMA Regional Cancer Center, Community Health Network (Community Regional Cancer Care), OhioHealth, MemorialCare, Mercy (David C. Pratt Cancer Center)
Poster Board: 518; Abstract number for publication: 8044


● Impact of FGFR3 Pathway Activation in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.
Presenter: Earle F Burgess, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Collaborating Institutions: GeneCentric Therapeutics
Poster Board: 75; Abstract number for publication: 4596


● Improved Clinical outcomes with ERBB2 gene amplification and activating mutations in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy
Presenter: Earle F Burgess, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Poster Board: 74 Abstract number for publication: 4595


● Molecular Classification of Neuroendocrine Carcinoma of the Bladder
Presenter: Shijia Li, Bridgeport Hospital
Collaborating Institutions: University of California San Francisco
Poster Board: 107; Abstract number for publication: 4628


● Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presenter: Emmanuel S. Antonarakis, University of Minnesota
Collaborating Institutions: University of Utah, University of California San Diego
Poster Board: 184; Abstract number for publication: 5089


● Actionable genomic alterations and outcomes in lung squamous and adenosquamous cell carcinoma
Presenter: Simone E. Dekker, University of Washington/Fred Hutchinson Cancer Center
Collaborating Institutions: City of Hope Cancer Center
Poster Board: 422; Abstract number for publication: 8632


● GEMINI-NSCLC: Multiomics and single-cell spatial profiling to benchmark, back-translate, and build digital twins of IO response
Presenter: Vincent Perez, Tempus AI Inc.
Collaborating Institutions: AstraZeneca, Mount Sinai Health System, The Ohio State University, University of California, Los Angeles (UCLA), City of Hope, Medical University of South Carolina (MUSC)
Poster Board: 323; Abstract number for publication: 8533
​
​

Monday, June 1st

9:00 am – 12:00 pm CT
​
Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Presenters: Alex Bataller, The University of Texas MD Anderson Cancer Center
Poster Board: 363; Abstract number for publication: 6570


AQUARIUS: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients with Hematologic Malignancies
Presenter: Michael A. Thompson, Tempus AI, Inc.
Collaborating Institutions: The Follicular Lymphoma Foundation, IFLI
Poster Board: 599a; Abstract number for publication: TPS7105
​
​
1:30 pm – 4:30 pm CT
​
● Concurrent RNA- and DNA-NGS testing for the detection of clinically-relevant fusions in pediatric solid-tumor patients
Presenter: Lisa Gai, Tempus AI Inc.
Collaborating Institutions: University of Texas Southwestern Medical Center, Pediatrics, UCLA Medical Center
Poster Board: 286; Abstract number for publication: # 10035


● Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (mBC)
Presenter: Shivani K Thaker, UCLA Health Jonsson Comprehensive Cancer Center
Collaborating Institutions: Cedars-Sinai Medical Center, University of Texas MD Anderson Cancer Center, City of Hope, Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute, Baylor College of Medicine
Poster Board: 144; Abstract number for publication: 1030


GEMINI-BREAST: Evaluating Minimal Residual Disease (MRD) through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Presenter: Matthew E. Campbell, Tempus AI, Inc.
Collaborating Institutions: The Ohio State University, PIH Health Whittier Hospital, Mayo Clinic Rochester
Poster Board: 130b; Abstract number for publication: TPS649


◆ Biology-informed predictive modeling and resistance monitoring in trastuzumab deruxtecan–treated metastatic breast cancer
Presenter: Josh Wheeler, Genialis, Inc.
Poster Board: 137; Abstract: 1023

Saturday, May 30th

9:00 am – 12:00 pm CT
​
Germline pathogenic/likely pathogenic (P/LP) variants in epithelial neuroendocrine neoplasms: The case for universal germline genetic testing
Presenter: Udhayvir S. Grewal, Winship Cancer Institute of Emory University
Poster Board: 135
Abstract number for publication: 4182
​
​

Sunday, June 1st

9:00 am – 12:00 pm CT
​
Germline testing in Asian American and Pacific Islander women with breast cancer
Presenter: Jennifer Tseng, City of Hope Orange County
Poster Board: 566
Abstract number for publication: 10605


Actionable Germline Findings in Endometrial Cancer from a Large Multigene Panel Tested Cohort
Presenter: Adela Rodriguez Hernandez, Dana-Farber Cancer Institute
Poster Board: 572
Abstract number for publication: 10611

The following abstracts were conducted on behalf of Personalis and may help inform understanding of the clinical performance and potential utility of xM (NeXT Personal® Dx).
​

Saturday, May 30th

9:00 am – 12:00 pm CT
​
Minimal residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: Updates from the VICTORI study
Presenter: João Solar Vasconcelos, MD
Presenter Affiliation: BC Cancer, University of British Columbia
Poster Board: 396; Abstract: 5611
​
​

Sunday, May 31st

9:00 am – 12:00 pm CT
​
Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma
Presenter: Juan Ruiz Bañobre
Presenter Affiliation: Complejo Hospitalario Universidad de Santiago
Poster Board: 30; Abstract: 4551


Ultrasensitive cDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy
Presenter: Christoffer Gebhardt
Presenter Affiliation: University Medical Center Hospital, Hamburg
Poster Board: 288; Abstract: 9572
​
​
9:00 am – 12:00 pm CT
​
Clinical validity of ultrasensitive single-digit parts per million cDNA detection in non-small cell lung cancer
Presenter: Jonathan Wan
Presenter Affiliation: Francis Crick Institute
Abstract: 8017
​
​

Monday, June 1st

9:00 am – 12:00 pm CT
​
Circulating tumor DNA enhances detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy
Presenter: Helen D. Clark, Amir A. Jazaer
Presenter Affiliation: University of Texas, MD Anderson Cancer Center
Poster Board: 233; Abstract: 5567


Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment
Presenter: Jeffrey How
Presenter Affiliation: University of Texas, MD Anderson Cancer Center
Poster Board: 277; Abstract: 5611